A Phase 1, First Time in Human (FTIH) Study to Evaluate GSK3352589, a REarranged During Transfection (RET) Growth Factor Receptor Tyrosine Kinase Inhibitor, in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 17, 2017

Primary Completion Date

March 5, 2018

Study Completion Date

March 5, 2018

Conditions

Irritable Bowel Syndrome

Interventions

DRUG

GSK3352589

It will be available in the dose of 1, 5, 25 and 100 mg tablet for oral administration.

DRUG

Matching Placebo

It will be available across all strengths to match active drug in the form of tablet for oral administration.

Trial Locations (1)

GSK Investigational Site, Adelaide